ALSO NOTED: Thai FDA chief quits after one week; Congress asks FDA to nuke self-labeling rule

> In the midst of a controversy over patent-busting compulsory licenses, Thailand's new Food and Drug Administration chief quit after one week on the job. Report

> Seventeen House members asked FDA chief Andrew von Eschenbach to withdraw proposed rules that would allow drug makers to make their own changes to product labels; the reps said they feared the change would limit consumers' access to information about safety risks. Report

> Denmark's Lundbeck reported a 69 percent decline in fourth-quarter profits to $19 million, due to a writedown in value of its manufacturing facility in northern England. Report

> Federal prosecutors fined Florida-based White Broadman $1 million for selling unapproved ED drugs. Report

> The FDA gave its blessing to three new strengths of Endo Pharmaceuticals' Opana ER pain med. Report

> In other Endo news, the company removed Vice President Bill Newbould from his role as company spokesperson after he told a reporter that the company isn't evaluating a possible sale; because he wasn't privy to the discussions, Endo said, Newbould didn't know that the board had worked with financial advisers and consultants on a possible deal. Report

> The breast cancer remedy tamoxifen may be useful against bipolar disorder's mania phase, but side effects could pose difficulties for long-term use, researchers said. Release

> Eisai and its partners MGI Pharma and Helsinn Healthcare said the FDA gave the nod to their Aloxi injection to prevent post-operative nausea and vomiting. Release

> A Russian news service is reporting that Nycomed is looking for a site for a new pharmaceuticals plant in that country. Report

> Renovo's Juvista produced a mixed set of data in two mid-stage trials. Report

> Shire Human Genetic Therapies and a string of smaller drug developers have decided to pull up stakes from Cambridge and head for the suburbs. The exodus is being triggered by a desire to find less expensive digs. Report

> The Boston Globe weighs in with a lengthy look at the tussle over biogenerics--a.k.a. follow-ons and biosimilars. The smart money is betting that at some point in the not-too-distant future Congress will get around to giving the FDA authority to approve biogenerics on a case-by-case basis. Report

And Finally... If the presidential candidates were pharma brands, what would they be named? Hopium, for one. Report

Suggested Articles

Horizon Therapeutics has notched an FDA approval for its rare eye disease med Tepezza (teprotumumab), a possible blockbuster drug in the making.

Eli Lilly has a pipeline stuffed with a host of assets and has decided it needs a new injectable drug and device plant to manufacture some of them.

After Clovis’ Rubraca snagged an FDA boost in prostate cancer last week, AZ and Merck’s rival Lynparza has matched it with a boost of its own.